Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer and the potential place for growth hormone receptor antagonist therapy.

Literature DB >> 11527083

Cancer and the potential place for growth hormone receptor antagonist therapy.

Abstract

Pegvisomant is a recombinant protein, structurally similar to natural human growth hormone (GH), which is capable of binding to the GH receptor as a competitive antagonist. As well as being evaluated for the treatment of acromegaly, pegvisomant is being investigated as a possible antineoplastic agent, initially in mice. So far, in vitro efficacy against meningioma and in vivo efficacy against colon and breast cancer cell lines have been examined.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2001 PMID： 11527083 DOI： 10.1016/s1096-6374(01)80020-4

Source DB: PubMed Journal: Growth Horm IGF Res ISSN： 1096-6374 Impact factor: 2.372

Keyword Cloud
Cited

12 in total

Review 1. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Authors: Deepali Sachdev; Douglas Yee
Journal: J Mammary Gland Biol Neoplasia Date: 2006-01 Impact factor: 2.673

Review 2. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.

Authors: Jordi Rodon; Victoria DeSantos; Robert Jean Ferry; Razelle Kurzrock
Journal: Mol Cancer Ther Date: 2008-09 Impact factor: 6.261

3. Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.

Authors: Federica Guaraldi; Valentina Corazzini; Gary L Gallia; Silvia Grottoli; Karen Stals; Nadezhda Dalantaeva; Lawrence A Frohman; Márta Korbonits; Roberto Salvatori
Journal: Pituitary Date: 2012-12 Impact factor: 4.107

Review 4. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors: David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal: Endocr Rev Date: 2008-12-15 Impact factor: 19.871

Review 5. Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.

Authors: Kevin C J Yuen; Anthony P Heaney; Vera Popovic
Journal: Endocrine Date: 2016-01-05 Impact factor: 3.633

Cancer and the potential place for growth hormone receptor antagonist therapy.

Review 1. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Review 2. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.

3. Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.

Review 4. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Review 5. Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.

Review 6. The contribution of growth hormone to mammary neoplasia.

Review 7. Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function.

Review 8. Targeting growth hormone function: strategies and therapeutic applications.

Review 9. Dual Characters of GH-IGF1 Signaling Pathways in Radiotherapy and Post-radiotherapy Repair of Cancers.

10. Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma.